FP5Индивидуална стипендия2002–2003

Efficiency of ctl response induction by dc-subsets

5РП — Човешки потенциал в науката

Период
2002-01-01 → 2003-12-31
Финансиране от ЕС
140 550 €
Участници
1
Схема
RGI

Линиите свързват координатора с партньорите.

Накратко на български

Дендритните клетки се изследват, за да се разбере кои от техните видове най-ефективно активират имунната система срещу тумори. Това помага за подобряване на ваксините и методите за борба с раковите заболявания и инфекциите.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Цел на проекта

Dendritic cells (DC) are the professional antigen presenting cells of the immune system that instruct and control the activation of B and T lymphocytes, the mediators of specific immunity. DC are highly mobile cells and by their sequential migration from peripheral tissues to lymphoid organs they serve as sentinels of the immune system. Their extremely potent capacity to initiate and modulate immunity is currently exploited to fight infectious and autoimmune diseases as well as cancer. It is now well established that multiple distinct DC subsets exist. Moreover, it is well appreciated that the DC subset and the microenvironment a DC encounters in the periphery, determine the type of immune response that is induced, ranging from a TH1 or TH2 response to regulatory T cells and immune tolerance. The purpose of this project is to investigate the potential of different DC-subsets to induce an effective CTL mediated anti-tumor immune response in vivo and to characterize the type and magnitude of the induced immune response. The plan of investigation consists of comparing DC-subsets with respect to their ability to:1) migrate into lymphoid tissues and their localization within these tissues (using green fluorescent protem (GFP)-DC and Indium-111 labeled DC);2) induce an immune response against the foreign antigen ovalbumin (OV A) or the self antigen Tyrosinase Related Protein-2 (TRP-2),3) their vaccine efficacy in tumor models (B 16-OVA model and the fully autologous B 16- TRP-2 tumor model). We shall determine the quality and the magnitude of the induced responses using MHC-tetramers and cytokine assays.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз